Imperial College London
Dr Neil Murphy

DrNeilMurphy

Faculty of Medicine, School of Public Health

Honorary Senior Research Fellow
 
 
 
//

Contact

 

neil.murphy

 
 
//

Location

 

Norfolk PlaceSt Mary's Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Rothwell:2021:10.1016/j.cgh.2021.10.016,
author = {Rothwell, JA and Jenab, M and Karimi, M and Truong, T and Mahamat-Saleh, Y and Ferrari, P and Dashti, SG and Kühn, T and Cross, AJ and Severi, G and Gunter, MJ and Murphy, N},
doi = {10.1016/j.cgh.2021.10.016},
journal = {Clinical Gastroenterology and Hepatology},
title = {Metabolic syndrome and risk of gastrointestinal cancers: an investigation using large-scale molecular data},
url = {http://dx.doi.org/10.1016/j.cgh.2021.10.016},
volume = {20},
year = {2021}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - BACKGROUND AND AIMS: Gastrointestinal cancer risk is influenced by the presence of metabolic syndrome [MetS]. However, previous epidemiological studies lacked full serological biomarker data for the classification of MetS and the interaction of MetS with germline cancer risk variants is unknown. METHODS: We investigated the associations between MetS and gastrointestinal cancer risk (overall, colorectal, pancreatic, esophageal adenocarcinoma, esophageal squamous cell carcinoma, stomach cardia, stomach non-cardia, hepatocellular carcinoma, and intrahepatic bile duct cancer) in 366,016 UK Biobank participants with comprehensive serum biomarker and genotype data. MetS status was determined by three different definitions at baseline and, in 15,152 participants, at a repeat assessment after a median of 4.3 years of follow-up. Multivariable hazard ratios [HR] and 95% confidence intervals [CI] for cancer outcomes were estimated using Cox proportional hazards models. Analyses stratified by polygenic risk score [PRS] were conducted for colorectal and pancreatic cancers. RESULTS: During a median follow-up of 7.1 years, 4,238 incident cases of a gastrointestinal cancer occurred. MetS at baseline was associated with higher risk of overall gastrointestinal cancer by any definition (HR 1.21, 95% CI 1.13-1.29, harmonized definition). MetS was associated with increased risks of colorectal cancer, colon cancer, rectal cancer, hepatocellular carcinoma, pancreatic cancer in women, and esophageal adenocarcinoma in men. Associations for colorectal cancer and pancreatic cancer did not differ by PRS strata (P-heterogeneity 0.70 and 0.69, respectively), and 80% of participants with MetS at baseline retained this status at the repeat assessment. CONCLUSIONS: These findings underscore the importance of maintaining good metabolic health in reducing the burden of gastrointestinal cancers, irrespective of genetic predisposition.
AU  - Rothwell,JA
AU  - Jenab,M
AU  - Karimi,M
AU  - Truong,T
AU  - Mahamat-Saleh,Y
AU  - Ferrari,P
AU  - Dashti,SG
AU  - Kühn,T
AU  - Cross,AJ
AU  - Severi,G
AU  - Gunter,MJ
AU  - Murphy,N
DO  - 10.1016/j.cgh.2021.10.016
PY  - 2021///
SN  - 1542-3565
TI  - Metabolic syndrome and risk of gastrointestinal cancers: an investigation using large-scale molecular data
T2  - Clinical Gastroenterology and Hepatology
UR  - http://dx.doi.org/10.1016/j.cgh.2021.10.016
UR  - https://www.ncbi.nlm.nih.gov/pubmed/34687971
UR  - https://www.sciencedirect.com/science/article/pii/S1542356521011290?via%3Dihub
UR  - http://hdl.handle.net/10044/1/92678
VL  - 20
ER  -
Download